Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity

Cardiotoxic effects of angiogenesis inhibitors

(2021) Stephen J.H. Dobbin et al.   CLINICAL SCIENCE

Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors

(2021) Alan H. Baik et al.   CLINICAL SCIENCE

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

(2021) Daan C.H. van Dorst et al.   CIRCULATION RESEARCH

Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure

(2021) Leanne Mooney et al.   CLINICAL SCIENCE

Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?

(2021) Daan C.H. van Dorst et al.   CLINICAL SCIENCE

Interactions between cardiology and oncology drugs in precision cardio-oncology

(2021) Sailaja Kamaraju et al.   CLINICAL SCIENCE

Unravelling the tangled web of hypertension and cancer

(2021) Aristeidis Sionakidis et al.   CLINICAL SCIENCE

Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo

(2021) Petra Kollárová-Brázdová et al.   CLINICAL SCIENCE

Vascular toxicity associated with anti-angiogenic drugs

(2020) Karla B. Neves et al.   CLINICAL SCIENCE

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

(2015) Sarah J. Welsh et al.   Therapeutic Advances in Medical Oncology

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis

(2010) Tao Chen et al.   CANCER TREATMENT REVIEWS